CENTRAL LABORATORIES WHITE PAPERS & ARTICLES

• Combining Multiple Challenge Models Within A Single Individual

  Pairing immune challenges in healthy volunteers tests whether pharmacology is consistent across cells, tissue, and systemic responses before patient trials.

• What Most Psychiatric Drug Development Programmes Learn Too Late

  Clinical phase completion doesn’t end uncertainty. Six key questions on brain exposure, pharmacology, therapeutic window, and patient variability can reveal whether the molecule failed, or the mechanism.

• Redesigning Regulatory Medical Writing For The AI Era

  Faster drafts aren't faster submissions. See how to apply AI across medical writing with the governance and human review regulators expect.

• Early-Phase Lab Data: Why It Breaks And How To Prevent Risk

  Learn why lab data systems built quickly in early-phase trials tend to outlast their usefulness, quietly accumulating inconsistencies that surface only when scrutiny intensifies later in a study.

• Defining Meaningful Anti-Inflammatory Response: What Early Human Data Tells Us

  Controlled immune challenges link drug exposure to biological effects, helping refine dose selection, test mechanisms and support better decisions before patient trials.